Cargando…

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY

Detalles Bibliográficos
Autores principales:	Herrera, A. F., Lavie, D., Johnson, N. A., Avigdor, A., Borchmann, P., Andreadis, C., Bazargan, A., Gregory, G., Keane, C., Inna, T., Vucinic, V., Zinzani, P. L., Zhang, H., Pillai, P., Marinello, P., Timmerman, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430340/ http://dx.doi.org/10.1097/01.HS9.0000847216.85071.f3

Ejemplares similares

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
por: Timmerman, John, et al.
Publicado: (2023)

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
por: Garralda, E., et al.
Publicado: (2022)

1087. Evaluation of Risk Factors for Infection among Patients Receiving Ibrutinib
por: Tham, Kenneth, et al.
Publicado: (2020)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: Sasson, S. C., et al.
Publicado: (2021)

LHC MD 1087: Controlled Longitudinal Emittance Blow-up with Short Bunches
por: Timko, Helga, et al.
Publicado: (2017)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC)
por: Fratoni, Andrew J, et al.
Publicado: (2021)

Detailed characterization of the 1087 MeV/nucleon $^{56}Fe$ beam used for radiobiology at the AGS
por: Zeitlin, C, et al.
Publicado: (1997)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

Single nucleotide polymorphism at −1087 locus of interleukin-10 gene promoter is associated with severe chronic periodontitis in nonsmoking patients
por: Crena, Jasmine, et al.
Publicado: (2015)

1087. Fluoroquinolone Prophylaxis vs. No Bacterial Prophylaxis in Hospitalized Neutropenic Patients Undergoing Induction Chemotherapy for Acute Myeloid Leukemia
por: Buchanan, Carley, et al.
Publicado: (2019)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Mechanisims of asthma and allergic disease – 1087. Serine protease activity of per a 10 is requried to activiate airway epithelial cells
por: Kale, Sagar Laxman, et al.
Publicado: (2013)

1087. Aortic Graft Infections Caused by Propionibacterium acnes at the Minneapolis Veterans Affairs Health Care System (MVAHCS) 2007–2017
por: El Rafei, Abdelghani, et al.
Publicado: (2018)

Pembrolizumab-Induced Anti-GBM Glomerulonephritis: A Case Report
por: El Yamani, Nidal, et al.
Publicado: (2023)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
por: Jurczak, Wojciech, et al.
Publicado: (2023)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

1087 Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined DTPa-HBV-IPV/Hib Vaccine in Canadian Aboriginal and non-Aboriginal Infants
por: Scheifele, David W., et al.
Publicado: (2014)

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
por: Garcia-Marquez, Maria A., et al.
Publicado: (2021)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Non‐parallel anti‐tumour effects of pembrolizumab: a case of cardial tamponade
por: Tachihara, Motoko, et al.
Publicado: (2019)

Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy
por: Onda, Asako, et al.
Publicado: (2019)

Atomic resolution structure of EhpR: phenazine resistance in Enterobacter agglomerans Eh1087 follows principles of bleomycin/mitomycin C resistance in other bacteria
por: Yu, Shen, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6drj88s5slaosl7isbuce0n6rn